AU2002219485A1 - An autologous anti-cancer vaccine - Google Patents

An autologous anti-cancer vaccine

Info

Publication number
AU2002219485A1
AU2002219485A1 AU2002219485A AU2002219485A AU2002219485A1 AU 2002219485 A1 AU2002219485 A1 AU 2002219485A1 AU 2002219485 A AU2002219485 A AU 2002219485A AU 2002219485 A AU2002219485 A AU 2002219485A AU 2002219485 A1 AU2002219485 A1 AU 2002219485A1
Authority
AU
Australia
Prior art keywords
cancer vaccine
autologous anti
autologous
vaccine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219485A
Inventor
Olga Drize
Shoshana Frankenburg
Michal Lotem
Tamar Peretz
Eitan Shiloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of AU2002219485A1 publication Critical patent/AU2002219485A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002219485A 2001-01-08 2002-01-06 An autologous anti-cancer vaccine Abandoned AU2002219485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14079601A IL140796A0 (en) 2001-01-08 2001-01-08 An autologous anti-cancer vaccine
IL140796 2001-01-08
PCT/IL2002/000012 WO2002053176A2 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine

Publications (1)

Publication Number Publication Date
AU2002219485A1 true AU2002219485A1 (en) 2002-07-16

Family

ID=11075015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219485A Abandoned AU2002219485A1 (en) 2001-01-08 2002-01-06 An autologous anti-cancer vaccine

Country Status (3)

Country Link
AU (1) AU2002219485A1 (en)
IL (1) IL140796A0 (en)
WO (1) WO2002053176A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655216B2 (en) 2007-02-26 2010-02-02 University of Pittsburgh - of the Commonwealth of Higher Education Vaccine for activating helper function of CD8+ Tcells
EA200700598A1 (en) 2007-03-07 2007-12-28 Петр Генриевич ЛОХОВ ANTI-TUMOR VACCINE, METHOD FOR OBTAINING ANTI-TUMOR VACCINE AND METHOD FOR CARRYING OUT ANTITUMOR IMMUNOTHERAPY
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
CL2007002825A1 (en) 2007-09-28 2008-05-30 Univ De Chile Oncobiomed METHOD FOR GENERATING VACCINES THAT STIMULATE THE IMMUNE SYSTEM THAT INCLUDES INDUCTING PERIPHERAL BLOOD MONONUCLEAR CELLS TO BE DIFFERENTIATED FROM APC, THEN, SEPARATE SUCH APC AND MIX THEM WITH ADJUVANTS; EXTRACT OF TUMOR CELLS; AND COMP
AU2012257377B2 (en) 2011-05-17 2017-09-07 Hadasit Medical Research Services And Development Ltd. Allogeneic tumor cell vaccination
AU2013215116A1 (en) * 2012-02-02 2014-08-21 Caladrius Biosciences Pluripotent germ layer origin antigen presenting cancer vaccine
CN103372203B (en) * 2012-04-17 2015-05-06 国家纳米科学中心 Antigen composition, preparation method and application of antigen composition and tumour vaccine
CN103800896A (en) * 2012-11-15 2014-05-21 厦门鹭佳生物科技有限公司 Preparation method and application of autologous tumor vaccine
CA2942609A1 (en) 2014-03-17 2015-09-24 Richard Kroczek A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
CN106795492A (en) * 2015-06-17 2017-05-31 深圳市达科为生物工程有限公司 A kind of preparation method of tumor-specific CTL

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1991097A (en) * 1996-03-15 1997-10-01 Immunotherapy, Inc. Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
US6428782B1 (en) * 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment

Also Published As

Publication number Publication date
WO2002053176A2 (en) 2002-07-11
WO2002053176A3 (en) 2002-12-19
IL140796A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
AU2002236159A1 (en) Immunogenic complex
AU2002254558A1 (en) Novel vaccine
AU2002359919A1 (en) Syringe
AU2002361092A1 (en) Syringe
AU2003282498A1 (en) Hiv vaccine formulations
AU2003301850A1 (en) Hiv vaccine
AU2003285320A1 (en) Vaccine
AU2002219485A1 (en) An autologous anti-cancer vaccine
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU2002333276A1 (en) Drugs for vasculopaties
AU2001267541A1 (en) Vaccine composition
AU2002254161A1 (en) M cell directed vaccines
AU2003237701A1 (en) Vaccines
AU2002236065A1 (en) Papillomavirus vaccines
AU2002232078A1 (en) Clostridium difficile vaccine
AU2002349142A1 (en) Syringe
AU2002354943A1 (en) Haptenizing cancer cell components for the preparation of cancer vaccines
AU2002303093A1 (en) Mycobacterial vaccines
AU2002347346A1 (en) Dna vaccine
AU2002315309A1 (en) Vaccine against tuberculosis
AU2002355913A1 (en) Anti-tumor vaccines
AU2002361450A1 (en) Novel pharmaceutical
AU2002306879A1 (en) Cytoskeleton-associated proteins
AU2002253048A1 (en) Novel vaccine
AU2002337263A1 (en) Anti-coronavirus vaccine

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase